The GLP-1 Protocol

Several newer medications, including Ozempic, Wegovy and Zepbound, belong to a class called GLP-1 receptor agonists, and they have changed how doctors treat obesity and diabetes. This guide, written by Dr. Alexandra Sowa, explains the science behind these drugs, how they act in the body, and the health effects that reach beyond weight loss. It is written for medical professionals and general readers alike, and it links the science to everyday choices about lifestyle and treatment.

The book is organized as a practical user guide. It describes what taking a GLP-1 medication is like day to day, who may be a good candidate, and how to obtain a prescription and find out whether insurance will cover it. It also covers the common side effects and ways to reduce them, along with food plans and strategies for the mental difficulties of losing weight. Companion recipes, exercise advice and habits meant to help people keep weight off over the long term round out the guidance.

The author addresses a gap that she sees among patients. The source notes that nearly half of Americans qualify for these drugs and that one in eight has tried one, yet many get prescriptions from online pharmacies, med spas or general practitioners and then struggle to use them well over time. The book also takes on the flood of misleading information and sensational headlines about these medications, sorting the reliable material from the rest.

The guide suits anyone who is considering a GLP-1 medication, is already taking one, or wants a clearer picture of how these drugs might fit into their health plan.